These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6170196)

  • 21. Synergistic effect of immune gamma-globulin fraction on protection by antibiotic against corneal ulcers in experimental mice infected with Pseudomonas aeruginosa.
    Kawaharajo K; Homma JY
    Jpn J Exp Med; 1976 Jun; 46(3):155-65. PubMed ID: 822190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice.
    Petit JC; Sicard D; Bayo S; Daguet GL
    Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of a polyvalent erythrocyte diagnostic agent based on the antigens of Pseudomonas aeruginosa slime].
    Aleksandrova IA; Moroz AF; Antsiferova NG; Aleksandrov AD
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):72-5. PubMed ID: 3099518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.
    Pollack M
    J Infect Dis; 1983 Jun; 147(6):1090-8. PubMed ID: 6406615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
    Jones RJ; Hall M; Ricketts CR
    Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa.
    Johnston LJ; Syeklocha D
    Can J Microbiol; 1972 Oct; 18(10):1607-11. PubMed ID: 4628185
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunological study of antisera to to artificial O-antigen of Pseudomonas aeruginosa.
    Edvabnaya LS; Stanislavskii ES; Lany B; Schiller B; Bichowicz I
    J Hyg Epidemiol Microbiol Immunol; 1981; 25(2):163-8. PubMed ID: 6166668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type-specific immunity in pseudomonas diseases.
    Crowder JG; Fisher MW; White A
    J Lab Clin Med; 1972 Jan; 79(1):47-54. PubMed ID: 4621414
    [No Abstract]   [Full Text] [Related]  

  • 29. Pseudomonas aeruginosa antibodies in human plasma.
    Doi T; Yoshioka M; Nakajima T
    Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization against Pseudomonas in infection after thermal injury.
    Wesley J; Fisher A; Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S152-8. PubMed ID: 4138646
    [No Abstract]   [Full Text] [Related]  

  • 31. Slime glycolipoproteins and the pathogenicity of various strains of Pseudomonas aeruginosa in experimental infection.
    Dimitracopoulos G; Bartell PF
    Infect Immun; 1980 Nov; 30(2):402-8. PubMed ID: 6777303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antigenic complexes of Pseudomonas aeruginosa slime: their isolation and biological properties].
    Aleksandrov AD; Antsiferova NG; Zhmyrina TI; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):14-9. PubMed ID: 6422680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Passive hemagglutination reaction test using formalinized sheep erythrocytes treated with tannic acid and coated with proteast or elastase of Pseudomonas aeruginosa.
    Homma JY; Tomiyama T; Sano H; Hirao Y; Saku K
    Jpn J Exp Med; 1975 Oct; 45(5):361-5. PubMed ID: 817055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 35. Type-specific indirect hemagglutinating antibody in patients with Pseudomonas aeruginosa Infection.
    Shigeta S; Yasunaga Y; Ogata M
    J Clin Microbiol; 1978 Nov; 8(5):489-95. PubMed ID: 103887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A factor in human gamma globulin preparations active against Pseudomonas aeruginosa infect. in mice.
    MILLICAN RC; ROSENTHAL SM; RUST J
    Proc Soc Exp Biol Med; 1957 Jan; 94(1):214-7. PubMed ID: 13400919
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-gamma globulins and chronic infection: comparative studies of the immune response to various bacteria and gamma globulin preparations.
    Williams RC; Mellbye OJ; Kronvall G
    Infect Immun; 1972 Sep; 6(3):316-23. PubMed ID: 4404684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.